An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trial  by Durgam, Suresh et al.
Schizophrenia Research 152 (2014) 450–457
Contents lists available at ScienceDirect
Schizophrenia Research
j ourna l homepage: www.e lsev ie r .com/ locate /schresAn evaluation of the safety and efﬁcacy of cariprazine in patients with
acute exacerbation of schizophrenia: A phase II, randomized
clinical trialSuresh Durgam a,⁎, Anju Starace a, Dayong Li a, Raffaele Migliore a, Adam Ruth b,
György Németh c, István Laszlovszky c
a Forest Research Institute, Harborside Financial Center, Plaza V, Jersey City, NJ, USA
b Prescott Medical Communications Group, 205 N. Michigan Ave, Suite 3400, Chicago, IL, USA
c Gedeon Richter Plc, H-1103 Budapest 10, Gyomroi u. 19-21, Hungary⁎ Corresponding author at: Forest Research Institute, Ha
V, Jersey City, NJ 07311, USA. Tel.: +1 201 427 8172; fax:
E-mail addresses: suresh.durgam@frx.com (S. Durgam
(A. Starace), dayong.li@frx.com (D. Li), raffaele.migliore@
aruth@prescottmed.com (A. Ruth), gy.nemeth@richter.hu
i.laszlovszky@richter.hu (I. Laszlovszky).
0920-9964 © 2013 The Authors. Published by Elsevier B.V
http://dx.doi.org/10.1016/j.schres.2013.11.041a b s t r a c ta r t i c l e i n f oArticle history:
Received 27 August 2013
Received in revised form 21 November 2013
Accepted 26 November 2013
Available online 10 January 2014
Keywords:
Cariprazine
Schizophrenia
Antipsychotic
Dopamine
D3
Introduction: Cariprazine is an orally active and potent D3 and D2 partial agonist with preferential binding to D3
receptors in development for the treatment of schizophrenia and bipolarmania. This study (NCT00694707) eval-
uated the efﬁcacy and safety of cariprazine in patients with acute exacerbation of schizophrenia.
Methods: This study was a multinational, double-blind, randomized, placebo- and active-controlled, ﬁxed-dose
trial. Patients were randomized to receive placebo, cariprazine 1.5 mg/d, cariprazine 3.0 mg/d, cariprazine
4.5 mg/d, or risperidone 4.0 mg/d (for assay sensitivity) for 6 weeks of double-blind treatment and 2 weeks of
safety follow-up. Primary and secondary efﬁcacy parameters were change from baseline to Week 6 in Positive
andNegative SyndromeScale (PANSS) total andGlobal Impressions-Severity of Illness (CGI-S) scores, respective-
ly. Safety parameters included adverse events (AEs), vital signs, laboratorymeasures, and extrapyramidal symp-
tom (EPS) scales.
Results: Of 732 randomized patients, 64% completed the study. PANSS total score improvement at Week 6 was
statistically signiﬁcant versus placebo for cariprazine 1.5 mg/d, 3.0 mg/d, and 4.5 mg/d (least squares mean dif-
ference [LSMD]:−7.6,−8.8,−10.4, respectively; p b 0.001; LOCF) and risperidone (−15.1, p b 0.001; LOCF);
signiﬁcant improvement on CGI-S was demonstrated for all active treatments (p b 0.05). The most frequent
cariprazine AEs (≥5% and at least twice the rate of the placebo group) were insomnia, extrapyramidal disorder,
akathisia, sedation, nausea, dizziness, and constipation. Mean changes in metabolic parameters were small and
similar between groups.
Conclusion: The results of this study support the efﬁcacy and safety of cariprazine in patients with acute exacer-
bation of schizophrenia.© 2013 The Authors. Published by Elsevier B.V.Open access under CC BY-NC-ND license.1. Introduction
Schizophrenia is a multidimensional disorder with a heterogeneous
patient population that varies considerably in symptomatology, course
of illness, severity of disease, and associated medical and psychiatric
comorbidities (Tandon et al., 2009). While antipsychotic medications
are the cornerstone of schizophrenia treatment, effectiveness is limitedrborside Financial Center, Plaza
+1 201 427 8538.
), anju.starace@frx.com
frx.com (R. Migliore),
(G. Németh),
. Open access under CC BY-NC-ND licby unfavorable side effects, nonresponse to medication, and modest
efﬁcacy on negative symptoms (Kirkpatrick et al., 2006) and cognitive
impairment (Buchanan et al., 2005; Keefe et al., 2007). The Clinical
Antipsychotics Trials of Intervention Effectiveness (CATIE) schizophre-
nia study reported a 64–84% discontinuation rate with various antipsy-
chotic treatments (Lieberman et al., 2005; Stroup et al., 2006). While
patients may not adequately respond or tolerate initial treatment,
they may respond to a different antipsychotic, suggesting that there
may be underlying factors that inﬂuence individual outcomes with spe-
ciﬁc antipsychotic medications (Clark et al., 2011). Optimal manage-
ment of schizophrenia predicates the need for new compounds with
broader efﬁcacy and better safety proﬁles.
Although blockade of dopamine D2 receptors (either by a full
antagonist or partial agonist) is believed to be a necessary pharma-
cologic property shared by all antipsychotics (Nord and Farde, 2011),
afﬁnity for other neuroreceptors varies among available agents. These
pharmacological differences may help explain the variation in efﬁcacyense.
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receptor has emerged as an additional target for antipsychotic drug
treatment. High afﬁnity at the D3 receptor in combination with high
D2 receptor afﬁnity may offer the potential for augmented effect on
the cognitive deﬁcits and negative symptoms of schizophrenia (Joyce
and Millan, 2005; Laszy et al., 2005; Gyertyán et al., 2008; Kiss et al.,
2008).
Cariprazine is an orally active and potent dopamineD3 andD2 recep-
tor partial agonist with preferential binding to D3 receptors. In vitro,
cariprazine has almost 10-fold greater afﬁnity for D3 than D2 receptors
(Kiss et al., 2010). Cariprazine showed high and balanced occupancy
of both D3 and D2 receptors in rat brain in vivo at antipsychotic-like ef-
fective doses whereas other antipsychotics demonstrated high occu-
pancy at D2 and low or no occupancy at D3 receptors (Kiss et al.,
2012). Cariprazine has 2 major metabolites, desmethyl cariprazine
and didesmethyl cariprazine (Citrome, 2013), which have similar phar-
macological activity as the parent compound (data on ﬁle).
Cariprazine can be administered with or without food and is well
absorbed with peak plasma concentrations in 3–4 h (Citrome, 2013).
Elimination of cariprazine and its 2 major active metabolites is mainly
by hepatic metabolism via CYP3A4 (Citrome, 2013). Cariprazine and
its active metabolites show dose-proportional kinetics over the thera-
peutic dose range (Citrome, 2013). At steady state, didesmethyl
cariprazine is the prominent moiety, with exposure (AUC) about 3-
fold higher than cariprazine (data on ﬁle). Steady-state exposure of
desmethyl cariprazine is about 30 to 40% of cariprazine (Citrome,
2013). Steady state is reached in about 1 week for cariprazine and
desmethyl cariprazine (Citrome, 2013) and 4 weeks for didesmethyl
cariprazine (data on ﬁle). Upon dosing discontinuation, about 50%
reduction in plasma exposure of total active moieties occurs in about
1 week (data on ﬁle).
This Phase IIb trial (NCT00694707)was designed to explore the dose
range of cariprazine in the treatment of patients with acute exacerba-
tion of schizophrenia.
2. Methods
2.1. Study design
A 9-week, multinational, randomized, double-blind, placebo- and
active-controlled, parallel-group, ﬁxed-dose study was conducted
from June 2008 to August 2009 in patients with acute exacerbation of
schizophrenia. Patients were screened at 65 study centers in the
United States, India, Russia, Ukraine, and Malaysia. The study was con-
ducted in compliancewith the ICH-E6 Good Clinical Practice guidelines.
After a washout period of up to 7 days, patients were randomized
(1:1:1:1:1) to placebo, cariprazine 1.5 mg/d, cariprazine 3.0 mg/d,
cariprazine 4.5 mg/d, or risperidone 4.0 mg/d (included for assay sensi-
tivity) for 6 weeks of double-blind treatment. A 2-week safety period
followed during which patients were cross-titrated and stabilized on
appropriate medication as deemed necessary by the investigator.
Cariprazine was initiated at 1.5 mg/d and increased by 1.5 mg until
the target dose was reached (Day 2 or 3); risperidone was initiated at
2.0 mg/d and increased to 4.0 mg/d on Day 3.
Patients were hospitalized at screening and for at least 4 weeks of
double-blind treatment. Starting on Day 28, discharge was allowed
for patients with Clinical Global Impressions-Severity of Illness
(CGI-S) (Guy, 1976b) scores of 3 (mildly ill) or less, no signiﬁcant
risk of suicide or violent behavior, and were ready for discharge in
the opinion of the investigator; patients could be rehospitalized if
their condition worsened.
2.2. Patients
Patients (18 to 60 years) met Diagnostic and Statistical Manual of
Mental Disorders, fourth edition, text revision (DSM-IV-TR) (APA, 2000)criteria for schizophrenia (paranoid, disorganized, catatonic, or undiffer-
entiated type). Patients had the diagnosis for at least 1 year, current exac-
erbation less than 2 weeks' duration, and at least 1 psychotic episode
requiring hospitalization/antipsychotic medication change/intervention
during the preceding year. Patients experiencing aﬁrst episode of psycho-
sis were excluded. Positive and Negative Syndrome Scale (PANSS) (Kay
et al., 1987, 1991) total score between 80 and 120, a score≥4 (moderate)
on at least 2 of 4 PANSS positive symptoms (delusions, hallucinatory be-
havior, conceptual disorganization, suspiciousness/persecution), and
CGI-S rating ≥4 were required. Body mass index (BMI) between 18 and
35 was also required.
Exclusion criteria included diagnosis of various DSM-IV-TRdisorders
(e.g., schizoaffective, schizophreniform, bipolar I and II); alcohol/
substance abuse/dependence (within 3 months) was prohibited. Pa-
tients with treatment-resistant schizophrenia (poor response to≥2 an-
tipsychotics of adequate dose and duration) or suicidal or homicidal
attempt/intent (active or preceding 2 years) were excluded. Typical
treatment-related, concomitant medication, and medical/physical ex-
clusions were applied.
2.3. Concomitant medications
The use of psychotropic drugs (e.g., antipsychotics, neuroleptics,
antidepressants, stimulants, mood stabilizers, sedatives/hypnotics/
anxiolytics, dopamine-releasing drugs or dopamine agonists) was
not allowed. Zolpidem, zaleplon, chloral hydrate, or eszopiclone for
insomnia were permitted. Diphenhydramine, benztropine, or pro-
pranolol was permitted as rescue medication for extrapyramidal
(EPS) symptoms; lorazepam was permitted to control agitation,
restlessness, irritability, and hostility.
2.4. Outcome assessments
PANSS and CGI-S were administered at screening, baseline, and at
each visit (Weeks 1–6). Additionally, the 16-itemNegative Symptom
Assessment (NSA-16) (Axelrod et al., 1993) (baseline and Weeks 2,
4, and 6) and the Clinical Global Impressions-Improvement (CGI-I)
(Guy, 1976b) (Weeks 1–6) were administered.
Treatment-emergent adverse events (TEAEs) were recorded at all
visits. Additional safety assessments included physical examination,
laboratory evaluations, vital signs, weight, and 12-lead ECG. EPS was
monitored by the Abnormal Involuntary Movement Scale (AIMS)
(Guy, 1976a), Barnes Akathisia Rating Scale (BARS) (Barnes, 1989),
and Simpson-Angus Scale (SAS) (Simpson and Angus, 1970) at each
visit.
2.5. Statistical analysis
The Safety Population comprised all randomized patients who re-
ceived double-blind study medication. The Intent-to-Treat (ITT) Popu-
lation comprised patients in the Safety Population with a postbaseline
PANSS assessment; efﬁcacy analyses were based on the ITT Population.
The percentage of patients who prematurely discontinued was
compared between each active treatment group and placebo using
Fisher's exact test. Between-group differences for demographic pa-
rameters and baseline characteristics were analyzed using 2-way
analysis of variance (ANOVA) with treatment group and study center as
factors for continuous variables; the Cochran–Mantel–Haenszel (CMH)
test, controlling for study center, was used for categorical variables.
The primary efﬁcacy parameterwas change from baseline toWeek 6
in PANSS total score using the last observation carried forward (LOCF)
approach to impute missing postbaseline values. Between-group com-
parisons were conducted using an analysis of covariance model
(ANCOVA) with treatment group and study center as factors and base-
line PANSS total score as a covariate. To control overall type I error
rate, a sequential, stepwise, multiple-comparison procedure was used.
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was tested, followed by comparison of the individual cariprazine
3.0-mg and 4.5-mg groups versus placebo, and then the 1.5-mg
group versus placebo. Two sensitivity analyses based on observed
cases (OC) were performed using an ANCOVA model and a mixed-
effects model for repeated measures (MMRM). For MMRM, treatment
group, study center, visit, and treatment group-by-visit interaction
were ﬁxed effects and baseline value and baseline-by-visit interaction
were covariates. The secondary efﬁcacy parameter, CGI-S change from
baseline to Week 6, was analyzed using similar methods.
Additional efﬁcacy parameterswere change frombaseline toWeek 6
in NSA-16 total and Global Negative Symptom Rating, PANSS Positive
and Negative subscale scores, CGI-I score, and PANSS response (≥30%
improvement from baseline) atWeek 6. Additional efﬁcacy parameters
were analyzed by ANCOVA, except PANSS responder analysis, which
used a logistic regression model with treatment group and baseline
PANSS total score as explanatory variables.
Treatment-emergent EPS (parkinsonism) was deﬁned as SAS
score ≤3 at baseline and N3 at any postbaseline assessment;
treatment-emergent akathisia was deﬁned as BARS score≤2 at base-
line and N2 at any postbaseline assessment. Mean changes in EPS
scales were analyzed using an ANCOVA model (without multiplicity
adjustment). The Kaplan–Meier method was used to estimate the
cumulative incidence rate of EPS-related AEs. All other safety param-
eters were analyzed using descriptive statistics only.
Risperidone and placebo were compared to assess assay sensitivity;
no testing was done to compare active treatment groups. All statistical
tests were 2-sided hypothesis tests performed at the 5% level of signiﬁ-
cance; all conﬁdence intervals (CIs)were 2-sided 95% CIs. For all efﬁcacy
measures, statistical signiﬁcance was deﬁned as p values b 0.05. Prima-
ry and secondary efﬁcacy measures were controlled for multiple com-
parisons; additional and by-visit efﬁcacy outcomes were not
controlled for multiple comparisons.3. Results
3.1. Patient disposition and demographics
A total of 1011patientswere screened for eligibility and 732patients
were randomized to receive treatment. Approximately 38% of patients
were enrolled in the United States, 22% in India, 22% in Russia, 16% in
Ukraine, and 3% in Malaysia.
Approximately 64% of patients completed the study. The most fre-
quent reasons for premature discontinuation are presented in Table 1.
Signiﬁcantly more placebo patients than cariprazine or risperidone pa-
tients discontinued due to insufﬁcient therapeutic response. Fewer
cariprazine and risperidone patients compared with placebo patients
discontinued because of AEs. AEs that led to discontinuation of 2 orTable 1
Patient disposition (Safety Population).
Placebo, n (%)
n = 151
Completed study 79 (52.3)
Premature discontinuation 72 (47.7)
Reason for discontinuation Adverse event 22 (14.6)
Insufﬁcient therapeutic response 33 (21.9)
Protocol violation 1 (0.7)
Withdrawal of consent 14 (9.3)
Lost to follow-up 0
Other 2 (1.3)
Entered safety follow-up 110 (72.8)
⁎ p b 0.05 vs placebo (Fisher's exact test).more patients in any group were schizophrenia, psychotic disorder,
and psychotic behavior, which occurred more frequently in placebo pa-
tients, and oromandibular dystonia, which occurred in 2 (1.4%) ris-
peridone patients.
There were no signiﬁcant differences in demographic characteristics
among treatment groups (Table 2). Baseline disease characteristics
were similar among groups except for a slight imbalance in previous
suicide attempts.
3.2. Efﬁcacy analyses
PANSS total score change frombaseline toWeek 6 (LOCF)was statis-
tically signiﬁcantly superior for each cariprazine group compared with
placebo (Table 3). Sensitivity analyses using MMRM and OC ANCOVA
approaches demonstrated the robustness of cariprazine superiority. Sta-
tistically signiﬁcant improvement was observed for cariprazine 3.0 and
4.5 mg/d versus placebo fromWeek 1 throughWeek 6 using LOCF and
MMRM analysis (Fig. 1); cariprazine 1.5 mg/d demonstrated statistical-
ly signiﬁcant improvement versus placebo fromWeek 2 throughWeek
6 (LOCF and MMRM). For the risperidone group, PANSS total score
change at Week 6 was statistically signiﬁcant versus placebo using
LOCF, MMRM, and OC ANCOVA.
Mean baseline CGI-S scores approached 5, indicating that the
study population was markedly ill. At Week 6, CGI-S scores were
statistically signiﬁcantly decreased in each cariprazine group and
the risperidone group relative to placebo using both LOCF and
MMRM approaches (Table 3).
All 3 doses of cariprazine showed statistically signiﬁcant im-
provement versus placebo on positive and negative symptoms as
measured by the PANSS Positive and Negative subscales, and the
NSA-16 (Table 3; Fig. 2). Relative to placebo, cariprazine groups
also had statistically signiﬁcantly lower CGI-I scores and greater
rates of response (Table 3). Risperidone also showed statistically sig-
niﬁcant advantage over placebo on secondary and additional efﬁcacy
measures.
3.3. Safety analyses
Themeanduration of treatmentwas 30.5 days for placebo, 33.3 days,
33.9 days, and 34.0 days for cariprazine 1.5, 3.0, and 4.5 mg/d, respec-
tively, and 35.0 days for risperidone.
3.3.1. Adverse events
An overall summary of AEs and commonly reported TEAEs during
double-blind treatment is presented in Table 4. The majority of the
TEAEs were considered mild in intensity (approximately 70% in each
group) and related to treatment. The most frequent TEAEs (≥5% and
at least twice the rate of the placebo group) in the cariprazine groupsCariprazine, n (%) Risperidone 4.0 mg/d, n (%)
n = 140
1.5 mg/d
n = 145
3.0 mg/d
n = 146
4.5 mg/d
n = 147
90 (62.1) 96 (65.8) 98 (66.7) 101 (72.1)
55 (37.9) 50 (34.2)⁎ 49 (33.3)⁎ 39 (27.9)⁎
14 (9.7) 8 (5.5)⁎ 12 (8.2) 13 (9.3)
18 (12.4)⁎ 17 (11.6)⁎ 15 (10.2)⁎ 10 (7.1)⁎
2 (1.4) 1 (0.7) 3 (2.0) 1 (0.7)
18 (12.4) 22 (15.1) 16 (10.9) 15 (10.7)
1 (0.7) 2 (1.4) 0 0
2 (1.4) 0 3 (2.0) 0
106 (73.1) 103 (70.5) 102 (69.4) 93 (66.4)
Table 2
Baseline demographic and disease characteristics (Safety Population).
Placebo
n = 151
Cariprazine Risperidone 4.0 mg/d
n = 140
1.5 mg/d
n = 145
3.0 mg/d
n = 146
4.5 mg/d
n = 147
Demographics
Age, mean (SD), years 36.0 (10.8) 36.8 (9.6) 37.1 (10.4) 35.8 (10.8) 36.5 (11.1)
Men, n (%) 101 (66.9) 93 (64.1) 107 (73.3) 103 (70.1) 98 (70.0)
Race, n (%)
White 80 (53.0) 77 (53.1) 71 (48.6) 75 (51.0) 67 (47.9)
Black/African American 34 (22.5) 32 (22.1) 38 (26.0) 32 (21.8) 35 (25.0)
Asian 36 (23.8) 34 (23.4) 37 (25.3) 39 (26.5) 37 (26.4)
Other 1 (0.7) 2 (1.4) 0 1 (0.7) 1 (0.7)
Weight, mean (SD), kg 74.4 (18.6) 71.7 (17.7) 74.8 (16.3) 72.4 (16.6) 75.1 (18.2)
BMI, mean (SD), kg/m2 25.2 (4.5) 24.9 (4.9) 25.6 (4.6) 24.8 (4.2) 25.8 (4.8)
Disease characteristics
Schizophrenia subtype, n (%)
Disorganized 9 (6.0) 5 (3.4) 7 (4.8) 4 (2.7) 8 (5.7)
Catatonic 0 0 0 1 (0.7) 1 (0.7)
Paranoid 130 (86.1) 131 (90.3) 132 (90.4) 134 (91.2) 121 (86.4)
Undifferentiated 12 (7.9) 9 (6.2) 7 (4.8) 8 (5.4) 10 (7.1)
Duration of schizophrenia, mean (SD), years 11.6 (9.7) 11.4 (8.7) 11.2 (8.6) 11.1 (9.8) 12.3 (9.9)
Number of previous psychiatric hospitalizations, mean (SD) 5.6 (5.7) 6.3 (8.4) 5.6 (6.5) 7.0 (8.6) 6.3 (8.1)
Suicide attempt history, n (%) 16 (10.6) 32 (22.1) 28 (19.2) 31 (21.1) 22 (15.7)
History of violence, n (%) 19 (12.6) 20 (13.8) 11 (7.5) 11 (7.5) 15 (10.7)
SD, standard deviation; BMI, body mass index.
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dizziness, and constipation; no clear relationship between cariprazine
dosages was observed.
A total of 21 SAEs were reported in 19 patients during double-blind
treatment. The only SAE reported in N1 patient was psychotic behavior
in the placebo group (3 patients). SAEs led to discontinuation in 13/19
patients (placebo, 5; cariprazine 1.5 mg/d, 4; cariprazine 4.5 mg/d, 1;
risperidone, 3). There were no deaths reported during double-blind
treatment; one patient died from cardio-respiratory arrest before taking
any dose of study medication.
During the safety follow-up period, newly-emergent AEs (AEs not
present before or worsening during the safety follow-up period) were
observed in 12 (8%) placebo patients, 17 (12%), 16 (11%), and 14
(10%) cariprazine 1.5 mg, 3.0 mg, and 4.5 mg patients, respectively,
and 9 (6%) risperidone patients. SAEs occurred in 17 patients during
safety follow-up, with psychotic disorder (placebo, 2) and schizophre-
nia (cariprazine 3.0 mg/d, 2) being the only SAEs reported in N1 patient
in any group.
3.3.2. Clinical laboratory parameters
Changes from baseline in alanine aminotransferase (ALT) levels
were higher in the active treatment groups versus placebo (mean [me-
dian], U/L: placebo, −0.6 [−1.0]; cariprazine 1.5 mg/d, 0.8 [1.0];
cariprazine 3.0 mg/d, 2.1 [1.0]; cariprazine 4.5 mg/d, 3.2 [2.0], risperi-
done, 4.7 [1.0]). No clinically meaningful changes were observed in
other liver function tests (alkaline phosphatase [AP], aspartate amino-
transferase [AST], bilirubin). No cariprazine patients and 1 risperidone
patient met Hy's law criteria (≥3 times upper normal limit [ULN] for
AST [36 U/L men or 45 U/L women] or ALT [37 U/L men or 48 U/L for
women], total bilirubin ≥2 times ULN [1.2 mg/dL], and AP b2 times
ULN [100 U/L men or 145 U/L women]) (FDA, 2009).
Mean changes from baseline in most metabolic parameters were
small and similar between groups (Table 5). Cariprazine relative to
placebo was not associated with increased rates of potentially clinically
signiﬁcant (PCS) changes inmetabolic parameters;more risperidone pa-
tients experienced PCS changes in LDL (N1.2 times ULN [130 mg/dL])
and total cholesterol (N1.3 times ULN [200 mg/dL]) than cariprazine or
placebo patients (LDL: placebo, 12/133 [9.0%]; cariprazine 1.5, 3.0, and
4.5 mg/d, 12/122 [9.8%], 11/125 [8.8%], and 5/131 [3.8%], respectively;
risperidone, 15/118 [12.7%]; total cholesterol: placebo, 5/134 [3.7%];cariprazine 1.5, 3.0, and 4.5 mg/d, 2/130 [1.5%], 5/130 [3.8%], and 7/142
[4.9%], respectively; risperidone. 11/126 [8.7%]).
No increase in mean prolactin levels was observed in cariprazine or
placebo groups; however, mean increase in prolactin levels was ob-
served in risperidone-treated patients (Fig. 3).
3.3.3. Vital sign evaluations
Mean changes in body weight and waist circumference were small
and generally similar among groups (Table 5). A higher percentage of
patients in each cariprazine group relative to placebo had PCS increases
in bodyweight (≥7% increase); no relationship to dosage was apparent
(Table 5). Risperidonewas associated with the highest incidence of PCS
weight gain. Mean changes in blood pressure and pulse were small and
similar among groups (Table 5).
3.3.4. Electrocardiography
Mean changes in ventricular heart rate were slightly higher with
cariprazine 4.5 mg/d (4.3 bpm) compared with placebo (0.3 bpm).
Risperidone-treated patients had greater mean increase in QTcB
andQTcF intervals (QTcB,+5.8 ms; QTcF,+5.1 ms) relative to patients
treated with cariprazine 1.5 mg/d (QTcB, −0.9 ms; QTcF, −1.2 ms),
cariprazine 3.0 mg/d (QTcB, −3.4 ms; QTcF, −3.1 ms), cariprazine
4.5 mg/d (QTcB, +2.1 ms; QTcF: −1.6 ms) and placebo-treated pa-
tients (QTcB,−1.1 ms; QTcF,−1.4 ms). No PCS postbaseline QTc pro-
longation (QTcB or QTcF N500 ms) was reported.
3.3.5. Extrapyramidal symptoms
The cumulative incidence rate of all EPS-related TEAEs was higher
for risperidone than for the other treatment groups (Fig. 4). There
were no signiﬁcant differences among groups on the BARS and SAS; a
slightly greater increase in the mean AIMS score was observed with
cariprazine 1.5 mg/d (+0.2) relative to placebo (−0.1), but no appar-
ent dose relationship was observed (−0.1 for cariprazine 3.0 and
4.5 mg/d). Relative to placebo, greater percentages of cariprazine and
risperidone patients had treatment-emergent EPS (parkinsonism) and
akathisia (Table 6). EPS-related TEAEs resulted in premature discontin-
uation of 7 patients (1 [0.7%] placebo; 3 [2.0%] cariprazine 1.5 mg/d; 0
[0%] cariprazine 3.0 mg/d; 0 [0%] cariprazine 4.5 mg/d; 3 [2.1%]
risperidone).
Table 3
Efﬁcacy outcomes (ITT Population).
Placebo
n = 148
Cariprazine Risperidone 4.0 mg/d
n = 138
1.5 mg/d
n = 140
3.0 mg/d
n = 140
4.5 mg/d
n = 145
PANSS total score
Baseline, mean ± SEM 97.3 ± 0.8 97.1 ± 0.8 97.2 ± 0.7 96.7 ± 0.8 98.1 ± 0.8
Change at Week 6, LSM ± SEM LOCF −11.8 ± 1.5 −19.4 ± 1.6 −20.7 ± 1.6 −22.3 ± 1.6 −26.9 ± 1.6
MMRM −13.3 ± 1.8 −21.3 ± 1.8 −21.5 ± 1.7 −23.8 ± 1.7 −29.3 ± 1.7
LSMD (95% CI) LOCF – −7.6 (−11.8,−3.3)⁎⁎⁎ −8.8 (−13.1,−4.6)⁎⁎⁎ −10.4 (−14.6,−6.2)⁎⁎⁎ −15.1 (−19.4,−10.8)⁎⁎⁎
MMRM – −8.0 (−12.9,−3.0)⁎⁎ −8.2 (−13.1,−3.2)⁎⁎ −10.5 (−15.4,−5.6)⁎⁎⁎ −16.0 (−20.9,−11.0)⁎⁎⁎
CGI-S
Baseline, mean ± SEMa 4.9 ± 0.1 4.7 ± 0.1 4.9 ± 0.1 4.8 ± 0.1 4.8 ± 0.1
Change at Week 6, LSM ± SEM LOCF −0.7 ± 0.1 −1.0 ± 0.1 −1.1 ± 0.1 −1.3 ± 0.1 −1.5 ± 0.1
MMRM −0.9 ± 0.1 −1.2 ± 0.1 −1.2 ± 0.1 −1.5 ± 0.1 −1.6 ± 0.1
LSMD (95% CI) LOCF – −0.4 (−0.6,−0.1)⁎⁎ −0.5 (−0.7,−0.2) ⁎⁎⁎ −0.6 (−0.9,−0.4)⁎⁎⁎ −0.8 (−1.1,−0.6)⁎⁎⁎
MMRM – −0.3 (−0.6,−0.0)⁎ −0.3 (−0.6,−0.0)⁎ −0.6 (−0.8,−0.3)⁎⁎⁎ −0.7 (−1.0,−0.4)⁎⁎⁎
PANSS Positive subscale
Baseline, mean ± SEM 25.4 ± 0.3 25.2 ± 0.3 25.5 ± 0.3 25.5 ± 0.3 25.4 ± 0.3
Change at Week 6, LSM ± SEM LOCF −4.1 ± 0.5 −6.1 ± 0.5 −7.0 ± 0.5 −7.5 ± 0.5 −9.5 ± 0.5
MMRM −4.7 ± 0.6 −6.8 ± 0.6 −7.4 ± 0.6 −8.3 ± 0.6 −10.3 ± 0.6
LSMD (95% CI) LOCF – −2.0 (−3.4,−0.6)⁎⁎ −2.9 (−4.3,−1.5)⁎⁎⁎ −3.4 (−4.8,−2.0)⁎⁎⁎ −5.4 (−6.8,−3.9)⁎⁎⁎
MMRM – −2.2 (−3.8,−0.5)⁎ −2.7 (−4.4,−1.1)⁎⁎ −3.6 (−5.2,−2.0)⁎⁎⁎ −5.6 (−7.3,−4.0)⁎⁎⁎
PANSS Negative subscale
Baseline, mean ± SEM 25.2 ± 0.4 24.3 ± 0.4 24.5 ± 0.4 24.5 ± 0.4 25.2 ± 0.4
Change at Week 6, LSM ± SEM LOCF −2.0 ± 0.4 −4.2 ± 0.4 −4.5 ± 0.4 −5.0 ± 0.4 −5.1 ± 0.4
MMRM −2.5 ± 0.4 −4.8 ± 0.4 −4.9 ± 0.4 −5.5 ± 0.4 −5.8 ± 0.4
LSMD (95% CI) LOCF – −2.2 (−3.2,−1.1)⁎⁎⁎ −2.5 (−3.5,−1.4)⁎⁎⁎ −3.0 (−4.0,−2.0)⁎⁎⁎ −3.1 (−4.2,−2.1)⁎⁎⁎
MMRM – −2.2 (−3.4,−1.0)⁎⁎⁎ −2.3 (−3.5,−1.1)⁎⁎⁎ −2.9 (−4.1,−1.7)⁎⁎⁎ −3.2 (−4.4,−2.0)⁎⁎⁎
NSA-16 total scoreb
Baseline, mean ± SEM 55.9 ± 0.9 55.2 ± 1.0 56.0 ± 1.0 54.9 ± 0.9 55.5 ± 1.1
Change at Week 6, LSM ± SEM LOCF −3.8 ± 0.8 −7.7 ± 0.8 −8.3 ± 0.8 −9.3 ± 0.8 −9.6 ± 0.8
MMRM −5.6 ± 0.9 −9.7 ± 0.9 −9.6 ± 0.9 −10.5 ± 0.9 −11.1 ± 0.9
LSMD (95% CI) LOCF – −3.9 (−6.1,−1.7)⁎⁎⁎ −4.6 (−6.8,−2.4)⁎⁎⁎ −5.5 (−7.6,−3.3)⁎⁎⁎ −5.9 (−8.1,−3.7)⁎⁎⁎
MMRM – −4.1 (−6.6,−1.6)⁎⁎ −4.0 (−6.5,−1.5)⁎⁎ −4.9 (−7.4,−2.4)⁎⁎⁎ −5.5 (−8.0,−3.0)⁎⁎⁎
NSA-16 Global Negative Symptom Ratingb
Baseline, mean ± SEM 4.1 ± 0.1 4.1 ± 0.1 4.0 ± 0.1 4.0 ± 0.1 4.1 ± 0.1
Change at Week 6, LSM ± SEM LOCF −0.3 ± 0.1 −0.6 ± 0.1 −0.6 ± 0.1 −0.6 ± 0.1 −0.7 ± 0.1
MMRM −0.5 ± 0.1 −0.8 ± 0.1 −0.7 ± 0.1 −0.7 ± 0.1 −0.8 ± 0.1
LSMD (95% CI) LOCF – −0.2 (−0.4,−0.1)⁎⁎ −0.3 (−0.5,−0.1)⁎⁎ −0.3 (−0.5,−0.1)⁎⁎⁎ −0.4 (−0.6,−0.2)⁎⁎⁎
MMRM – −0.2 (−0.4,−0.0)⁎ −0.2 (−0.4, 0.1) −0.2 (−0.4, 0.0) −0.3 (−0.5,−0.1)⁎⁎
CGI-I
Mean score at Week 6, LSM ± SEM LOCF 3.5 ± 0.1 3.0 ± 0.1 2.9 ± 0.1 2.8 ± 0.1 2.5 ± 0.1
MMRM 3.2 ± 0.1 2.8 ± 0.1 2.7 ± 0.1 2.5 ± 0.1 2.3 ± 0.1
LSMD (95% CI) LOCF – −0.5 (−0.8,−2.0)⁎⁎ −0.6 (−0.9,−0.3)⁎⁎⁎ −0.8 (−1.1,−0.5)⁎⁎⁎ −1.0 (−1.3,−0.7)⁎⁎⁎
MMRM – −0.4 (−0.8,−0.1)⁎⁎ −0.5 (−0.8,−0.2)⁎⁎ −0.7 (−1.0,−0.4)⁎⁎⁎ −1.0 (−1.3,−0.6)⁎⁎⁎
PANSS responders (≥30% improvement from baseline)
Responders, n (%) LOCF 28 (18.9) 44 (31.4)⁎ 50 (35.7)⁎⁎ 52 (35.9)⁎⁎⁎ 60 (43.5)⁎⁎⁎
SEM, standard error of the mean; LSM, least squares mean; LSMD, least squares mean difference; CI, conﬁdence interval; LOCF, last observation carried forward; MMRM, mixed-effects
model for repeated measures; PANSS, Positive and Negative Syndrome Scale; CGI-S, Clinical Global Impressions-Severity of Illness; NSA-16, 16-item Negative Symptom Assessment;
CGI-I, Clinical Global Impressions-Improvement.
a CGI-S scoreswere signiﬁcantly different among treatment groups at baseline (p = 0.045); the baseline score is used in the ANCOVAmodel, but the imbalance did not confound CGI-S
or CGI-I results.
b For NSA-16 total score and NSA-16 Global Negative Symptom Rating, the number of patients included in the analysis was: n = 145 (placebo), n = 138 (cariprazine 1.5 mg/d),
n = 136 (cariprazine 3.0 mg/d), n = 144 (cariprazine 4.5 mg/d), and n = 137 (risperidone 4.0 mg/d).
⁎⁎⁎ p ≤ 0.001 vs placebo.
⁎⁎ p ≤ 0.01 vs placebo.
⁎ p b 0.05 vs placebo.
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Cariprazine 1.5 mg/d, 3.0 mg/d, and 4.5 mg/d showed signiﬁcant
improvement relative to placebo on the primary and secondary efﬁcacy
parameters, change from baseline in PANSS total and CGI-S, respec-
tively. Cariprazine also demonstrated signiﬁcant improvement versus
placebo on the positive and negative symptoms of schizophrenia
(assessed by PANSS Positive, PANSS Negative, and NSA-16 scores).
Cariprazine was signiﬁcantly superior to placebo on all other additional
efﬁcacy parameters as well.In this cariprazine dose-ﬁnding study, dosages were selected based
on prior pharmacokinetic (Ereshefsky et al., 2008), PET receptor occu-
pancy (Potkin et al., 2009), and double-blind, placebo-controlled, ﬂexi-
ble high- (6 to 12 mg/d) and low- (1.5–4.5 mg/d) dose, proof-of-
concept studies in patients with schizophrenia (Litman et al., 2008).
Based on the results of these preliminary studies, relatively low
cariprazine doses were chosen to evaluate efﬁcacy in the present study.
While signiﬁcant improvement versus placebo was observed for
the lowest cariprazine dose (1.5 mg/d) tested, greater treatment
effects were observed with higher doses (3.0 mg/d and 4.5 mg/d);
Fig. 1. Change from baseline in PANSS total score (LOCF andMMRM, ITT Population). ITT,
intent-to-treat population; LOCF, last observation carried forward; LS, least squares;
MMRM,mixed-effects model with repeatedmeasures; PANSS, Positive and Negative Syn-
drome Scale; *p b 0.05; **p b 0.01; ***p b 0.001; vs placebo.
Fig. 2. Improvement in positive and negative symptoms (MMRM, ITT Population). LSMD,
least squares mean difference; PANSS, Positive and Negative Syndrome Scale; *p b 0.05;
**p b 0.01; ***p b 0.001; vs placebo.
Table 4
Treatment-emergent adverse events during double-blind treatment period (Safety
Population).
Placebo, %
n = 151
Cariprazine, % Risperidone
4.0 mg/d, %
n = 140
1.5 mg/d
n = 145
3.0 mg/d
n = 146
4.5 mg/d
n = 147
SAEsa, n (%) 7 (4.6) 5 (3.4) 0 4 (2.7) 3 (2.1)
TEAEs, n (%) 100 (66.2) 99 (68.3) 104 (71.2) 108 (73.5) 95 (67.9)
Most common TEAEs (≥5% of patients in any treatment group), n (%)
Insomnia 11 (7.3) 15 (10.3) 24 (16.4) 24 (16.3) 21 (15.0)
Extrapyramidal
disorder
7 (4.6) 13 (9.0) 13 (8.9) 17 (11.6) 18 (12.9)
Headache 16 (10.6) 16 (11.0) 10 (6.8) 12 (8.2) 12 (8.6)
Sedation 5 (3.3) 7 (4.8) 7 (4.8) 12 (8.2) 16 (11.4)
Akathisia 7 (4.6) 13 (9.0) 14 (9.6) 11 (7.5) 12 (8.6)
Nausea 5 (3.3) 7 (4.8) 11 (7.5) 11 (7.5) 8 (5.7)
Dizziness 3 (2.0) 5 (3.4) 3 (2.1) 9 (6.1) 8 (5.7)
Schizophrenia 13 (8.6) 7 (4.8) 6 (4.1) 9 (6.1) 1 (0.7)
Vomiting 5 (3.3) 4 (2.8) 9 (6.2) 8 (5.4) 4 (2.9)
Anxiety 5 (3.3) 6 (4.1) 8 (5.5) 7 (4.8) 3 (2.1)
Constipation 5 (3.3) 14 (9.7) 9 (6.2) 7 (4.8) 13 (9.3)
Tremor 5 (3.3) 5 (3.4) 6 (4.1) 3 (2.0) 10 (7.1)
Weight increased 1 (0.7) 3 (2.1) 5 (3.4) 0 7 (5.0)
AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
a SAEs occurred in 4 additional patients before the start of double-blind treatment, 3 of
which led to discontinuation.
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that higher doses of cariprazine may result in additional efﬁcacy
without compromising tolerability.
Risperidone, the active comparator, also demonstrated signiﬁcant
improvement relative to placebo on all measures, demonstrating assay
sensitivity and validating the study. The study was not designed to
detect differences between cariprazine and risperidone; mean changes
from baseline were larger in the risperidone group than for the
cariprazine or placebo groups on many parameters.
Weight gain, glucose dysregulation, and lipid abnormalities are com-
monly associated with atypical antipsychotic treatments and are likely
contributors to increased cardiovascular risk factors (Goff et al., 2005;
Daumit et al., 2008). In this study, cariprazine potentially showed a
more favorable weight gain proﬁle than risperidone. Changes in meta-
bolic (cholesterol, glucose, and triglycerides) parameters were small
and similar among placebo and cariprazine groups. Risperidone, but
not cariprazine, was associated with prolactin elevation. PCS changes
in ECG parameters were not seen in either cariprazine or risperidone
groups.
Greater percentages of both cariprazine and risperidone patients had
treatment-emergent EPS (parkinsonism) and akathisia relative to place-
bo. The cumulative incidence curve suggested that risperidone-treated
patients experienced more EPS-related TEAEs than cariprazine-treated
patients during the course of study.
This study was limited by its short treatment duration and ﬁxed-
dose design and lower dose range (from 1.5 to 4.5 mg/day). In real-
world clinical practice, clinicians adjust patient dosage based on
response, tolerability, and severity of illness.Cariprazine is a new antipsychotic candidate with high afﬁnity and
potent partial agonist activity at both D3 and D2 receptors with prefer-
ential binding to D3 receptors. Pharmacologically, it is most similar to
Table 5
Changes in vital signs and metabolic parameters (Safety Population).
Parameters Placebo
n = 151
Cariprazine Risperidone 4.0 mg/d
n = 140
1.5 mg/d
n = 145
3.0 mg/d
n = 146
4.5 mg/d
n = 147
Change from baseline to endpoint in liver function tests, mean change (SD)
ALT, U/L −0.6 (16.6) 0.8 (18.6) 2.1 (21.2) 3.2 (16.9) 4.7 (33.8)
AST, U/L −0.7 (10.2) −0.4 (10.9) 0.0 (11.2) 0.8 (10.4) 1.0 (21.7)
AP, U/L −3.8 (21.4) −4.7 (17.4) −0.8 (16.9) −4.3 (13.5) −3.1 (14.6)
Bilirubin, total, mg/dL 0.1 (0.3) 0.0 (0.3) 0.0 (0.3) 0.1 (0.3) 0.0 (0.5)
Change from baseline to endpoint in metabolic parameters, mean change (SD)
Total cholesterol, mg/dL −1.3 (30.4) −1.3 (32.2) −2.9 (34.3) −2.0 (27.7) 4.6 (34.6)
LDL cholesterol, mg/dL −0.1 (25.3) −1.1 (25.4) −1.6 (28.4) −1.7 (25.2) 3.8 (30.6)
HDL cholesterol, mg/dL −1.1 (9.4) 0.0 (10.7) −1.4 (12.0) 1.7 (9.8) −0.6 (10.1)
Triglycerides, mg/dL −3.1 (59.9) −5.3 (68.0) 0.3 (66.6) −6.8 (68.7) 6.3 (84.2)
Fasting glucose, mg/dL 3.3 (21.7) −0.1 (17.3) 0.8 (17.5) 5.1 (22.1) −0.9 (15.7)
Change from baseline to endpoint in vital signs, mean change (SD)
Systolic blood pressure, mm Hg 1.8 (11.0) 1.0 (9.0) −0.4 (9.6) 0.4 (10.6) −1.0 (10.4)
Diastolic blood pressure, mm Hg 0.3 (8.5) 0.4 (7.1) −0.6 (6.6) 0.3 (7.8) −1.1 (7.6)
Pulse, bpm 2.7 (11.3) 0.1 (10.4) 0.9 (11.1) −0.1 (11.5) 0.4 (11.8)
Body weight, kg 0.5 (2.9) 1.4 (2.9) 1.5 (3.5) 0.9 (2.9) 2.0 (3.2)
Waist circumference, cm 1.0 (11.5) 1.1 (3.0) 0.3 (2.4) −0.1 (7.0) 1.8 (8.4)
Proportion of patients with potentially clinically signiﬁcant weight gain, n/N (%)a
BMI 18.5 to b25 kg/m2 2/74 (2.7) 9/78 (11.5) 9/66 (13.6) 3/81 (3.7) 10/61 (16.4)
BMI 25 to b30 kg/m2 0 2/30 (6.7) 4/47 (8.5) 3/42 (7.1) 7/40 (17.5)
BMI ≥30 kg/m2 1/29 (3.4) 1/26 (3.8) 2/23 (8.7) 1/18 (5.6) 5/30 (16.7)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; BMI, bodymass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; n, number
of patients with a nonmissing baseline and at least one PCS postbaseline value during double-blind treatment, N, number of patients with a nonmissing baseline and at least one
nonmissing postbaseline value during double-blind treatment; PCS, potentially clinically signiﬁcant.
a The BMI categories of 18.5 to b25 kg/m2, 25 to b30 kg/m2, and≥30 kg/m2 represent normal, overweight and obese categories, respectively. Patients with BMI b18.5 are considered
underweight and were not included in this analysis (n = 24); only 1 patient from the underweight category had a 7% increase in weight (risperidone group).
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as a D2 partial agonist. Compared with aripiprazole, cariprazine has
higher afﬁnity to D3 and D2 receptors and shows higher potency in
in vitro functional assays and rodent behavioral models predictive of
antipsychotic-like activity (Kiss et al., 2010; Gyertyán et al., 2011). Ad-
ditionally, cariprazine but not aripiprazole showed high occupancy
of both D3 and D2 receptors in vivo (Gyertyán et al., 2011). Further
research is warranted to compare the clinical efﬁcacy, safety, and tol-
erability of cariprazine with aripiprazole and other atypical antipsy-
chotics (Zukin et al., 2012; Lieberman et al., 2013).
This 6-week trial supported the efﬁcacy and safety of cariprazine in
patients with acute exacerbation of schizophrenia. Given its unique
pharmacological proﬁle and positive past and present trial results,
cariprazine may be an important new option for the treatment of
schizophrenia.Fig. 3.Mean changes in prolactin levels by sex (Safety Population). Values indicate mean
change from baseline in prolactin (ng/mL).Role of funding source
This studywas funded by Forest Research Institute and Gedeon Richter Plc. The spon-
sorwas also responsible for the study design, implementation, analysis and interpretation
of data, decision to publish, and funding for editorial support.Contributors
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and interpretation of data. Anju Starace and Raffaele Migliore were involved in the con-
duct of the study and collection of data. György Nemeth and István Laszlovszky were in-
volved with the study design, analysis and interpretation of data. Dayong Li was
involved with statistical analysis of study data. Adam Ruth was involvedwith the analysis
and interpretation of data and provided editorial support on the manuscript. All authors
contributed to and have approved the ﬁnal manuscript.Fig. 4. Cumulative incidence rate of all EPS-related adverse events. Kaplan–Meier plot
representing cumulative incidence rates of EPS-related adverse events by time following
ﬁrst dose. EPS-related adverse events were akathisia, akinesia, bradykinesia, cogwheel ri-
gidity, dyskinesia, dystonia, extrapyramidal disorder, oromandibular dystonia, parkinson-
ism, muscle rigidity, tardive dyskinesia, and tremor. EPS, extrapyramidal symptoms.
Table 6
Treatment-emergent EPS adverse events (Safety Population).
Placebo, n (%)
n = 151
Cariprazine n (%) Risperidone
4.0 mg/d, n (%)
n = 140
1.5 mg/d
n = 145
3.0 mg/d
n = 146
4.5 mg/d
n = 147
Treatment-emergent EPS (parkinsonism)
SAS baseline ≤3 and postbaseline N3 7 (4.6) 15 (10.3) 12 (8.2) 12 (8.2) 14 (10.0)
Treatment-emergent akathisia
BARS baseline ≤2 and postbaseline N2 12 (7.9) 16 (11.0) 22 (15.1) 19 (12.9) 14 (10.0)
BARS, Barnes Akathisia Rating Scale; EPS, extrapyramidal symptoms; SAS, Simpson-Angus Scale; TEAE, treatment-emergent adverse event.
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